Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Therapies that modulate inflammation and fibrosis have the potential to reduce the morbidity and mortality associated with chronic kidney disease (CKD). A promising avenue may be manipulating thymosin-β4, a naturally occurring peptide, which is the major G-actin sequestering protein in mammalian cells and a regulator of inflammation and fibrosis. Thymosin-β4 is already being tested in clinical trials for heart disease and wound healing. This editorial outlines the evidence that thymosin-β4 may also have therapeutic benefit in CKD.

Original publication

DOI

10.1517/14712598.2015.1009891

Type

Journal article

Journal

Expert Opin Biol Ther

Publication Date

2015

Volume

15 Suppl 1

Pages

S187 - S190

Keywords

Ac-SDKP, fibrosis, inflammation, kidney disease, thymosin-β4, Adult, Animals, Fibrosis, Humans, Inflammation, Kidney, Mice, Rats, Renal Insufficiency, Chronic, Thymosin, Wound Healing